Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428248 | 0.93 | NAAA (0.40) | HCAR2NAAAGBA1CA1CA2 | |
| SCHEMBL4429473 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL4427552 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL4429493 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL4430759 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL4431935 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL4426715 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL4430261 | 0.91 | NAAA (0.43) | TSHRHCAR2NAAAGBA1CA1 | |
| SCHEMBL31053910 | 0.89 | ATM (0.34) | ATMTSHRADRB2ADRB1ADRB3 | |
| SCHEMBL11064469 | 0.87 | NAAA (0.33) | NAAAACHEGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544461-B2 | Near infrared ray activation type positive resin composition | KANSAI PAINT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| EP-1767993-B1 | Positive photosensitive composition and pattern forming method using the same | FUJIFILM CORP (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-7358030-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-20070259279-A1 | Near Infrared Ray Activation Type Positive Resin Composition | KANSAI PAINT CO., LTD. (JP) | 2007-11-08 | — | — | US | disclosed |
| CN-101027609-A | Positive resin composition of near-infrared-ray activation type | KANSAI PAINT CO LTD (JP) | 2007-08-29 | — | — | CN | disclosed |
| EP-1788432-A1 | POSITIVE RESIN COMPOSITION OF NEAR-INFRARED-RAY ACTIVATION TYPE | Kansai Paint Co., Ltd. (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060074262-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7015363-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040181097-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1415968-A1 | PROCESS FOR PRODUCING ETHER COMPOUND | Kyowa Yuka Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074262-A1 | Process for producing ether compound | AGL, ARL1, CYP2C8 | ATM 3315/4885TSHR 3842/4885ADRB2 844/4885 |
| US-20040181097-A1 | Process for producing ether compound | CYP2E1, ARL1, MRPL21 | ATM 4006/4885TSHR 4266/4885ADRB2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.